Cytomegalovirus-specific cell-mediated immunity for prediction of post-prophylaxis CMV disease in a phase 3 trial of letermovir vs valganciclovir prophylaxis in donor CMV-seropositive recipient CMV-seronegative kidney transplant recipients. (PubMed, Clin Infect Dis) - Dec 1, 2025 - "Among adult CMV high-risk D+R- KTRs who received prophylaxis, CMV-CMI by QFT-CMV increased over time. The result at the end of prophylaxis had limited clinical utility for identifying the risk for subsequent CMV disease."
Journal • P3 data • Cytomegalovirus Infection • Transplantation
|
|
Ajit P Limaye; Atul Humar; Barbara Haber; Marcus R Pereira; Marta Crespo; Nassim Kamar; Natalya Broyde; Robert P Carroll; Weiwen Wang
|